Emanuel C. Trabuco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emanuel C. Trabuco has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
John B. Gebhart
Mayo Clinic Department of OB/Gyn Division of Urogynecology Rochester Minnesota USA
11 shared publicationsAmy L. Weaver
Mayo Clin, Clin Trials & Biostat, Rochester, MN USA
10 shared publicationsChristopher J. Klingele
Obstetrics & Gynecology Olmsted Medical Center Rochester Minnesota USA
7 shared publications- John A. Occhino
Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN
4 shared publications Michaela E. McGree
Mayo Clin, Clin Trials & Biostat, Rochester, MN USA
4 shared publications- Sherif A. El Nashar
Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, FL
4 shared publications
Latest Publications
- 1 September 2026
- Published by Wiley in Neurourology and Urodynamics
Real‐World Results of Urethral Bulking With Polyacrylamide Hydrogel Versus Legacy Injectables: A Retrospective Study
Aims: Urethral bulking agents are established minimally invasive treatments for stress urinary incontinence (SUI), though efficacy varies among available materials. Comparative evidence on contemporary bulking agents, particularly polyacrylamide hydrogel (PAHG), remain limited. This study aimed to compare retreatment rates following primary periurethral bulking with PAHG versus other FDA‐approved agents. Methods: We performed a multicenter retrospective cohort study of women undergoing primary periurethral bulking for SUI or stress‐predominant mixed urinary incontinence between 2011 and 2024. Only current FDA‐approved bulking agents were included. The primary outcome was retreatment, defined as any subsequent anti‐incontinence procedure, including repeat bulking injections. Retreatment rates were estimated using Kaplan–Meier methods, with comparisons between PAHG and other agents, as well as between index and non‐index patients treated with PAHG. Cox proportional hazards models assessed predictors of retreatment. Results: Among 623 women undergoing periurethral bulking, 268 (43.0%) received PAHG, 332 (53.3%) calcium hydroxyapatite, 12 (1.9%) polydimethylsiloxane, and 11 (1.8%) carbon‐coated zirconium oxide. The median follow‐up was 2.2 years (IQR 0.9–6.6). Overall, 223 patients (36.6%) underwent retreatment at 2 years (80.7% with repeat bulking, 11.2% with urethral sling placement, and 8.1% underwent both repeat bulking and urethral sling placement). Bulking injection with PAHG was associated with lower retreatment rates compared with other agents (1‐year: 16.5% vs 34.8%; 2‐year: 24.4% vs 44.3%; p < 0.001). After adjusting for comorbidities and procedural factors, PAHG use remained independently associated with a reduced risk of retreatment (HR: 0.53, 95% CI: 0.38–0.75; p < 0.001) as did concomitant prolapse surgery (HR: 0.40, 95% CI: 0.22–0.72; p < 0.001). Retreatment rates following PAHG injection did not differ between index and non‐index patients ( p = 0.73). Conclusions: In this large multicenter cohort, PAHG was associated with significantly lower two‐year retreatment rates compared with other FDA‐approved bulking agents, with consistent effectiveness across index and non‐index patients. PAHG may represent a more durable bulking option than legacy agents for the treatment of SUI in real‐world practice, though long‐term data remains limited.
- 1 September 2026
- Published by Wiley in Neurourology and Urodynamics
Real‐World Results of Urethral Bulking With Polyacrylamide Hydrogel Versus Legacy Injectables: A Retrospective Study
Aims: Urethral bulking agents are established minimally invasive treatments for stress urinary incontinence (SUI), though efficacy varies among available materials. Comparative evidence on contemporary bulking agents, particularly polyacrylamide hydrogel (PAHG), remain limited. This study aimed to compare retreatment rates following primary periurethral bulking with PAHG versus other FDA‐approved agents. Methods: We performed a multicenter retrospective cohort study of women undergoing primary periurethral bulking for SUI or stress‐predominant mixed urinary incontinence between 2011 and 2024. Only current FDA‐approved bulking agents were included. The primary outcome was retreatment, defined as any subsequent anti‐incontinence procedure, including repeat bulking injections. Retreatment rates were estimated using Kaplan–Meier methods, with comparisons between PAHG and other agents, as well as between index and non‐index patients treated with PAHG. Cox proportional hazards models assessed predictors of retreatment. Results: Among 623 women undergoing periurethral bulking, 268 (43.0%) received PAHG, 332 (53.3%) calcium hydroxyapatite, 12 (1.9%) polydimethylsiloxane, and 11 (1.8%) carbon‐coated zirconium oxide. The median follow‐up was 2.2 years (IQR 0.9–6.6). Overall, 223 patients (36.6%) underwent retreatment at 2 years (80.7% with repeat bulking, 11.2% with urethral sling placement, and 8.1% underwent both repeat bulking and urethral sling placement). Bulking injection with PAHG was associated with lower retreatment rates compared with other agents (1‐year: 16.5% vs 34.8%; 2‐year: 24.4% vs 44.3%; p < 0.001). After adjusting for comorbidities and procedural factors, PAHG use remained independently associated with a reduced risk of retreatment (HR: 0.53, 95% CI: 0.38–0.75; p < 0.001) as did concomitant prolapse surgery (HR: 0.40, 95% CI: 0.22–0.72; p < 0.001). Retreatment rates following PAHG injection did not differ between index and non‐index patients ( p = 0.73). Conclusions: In this large multicenter cohort, PAHG was associated with significantly lower two‐year retreatment rates compared with other FDA‐approved bulking agents, with consistent effectiveness across index and non‐index patients. PAHG may represent a more durable bulking option than legacy agents for the treatment of SUI in real‐world practice, though long‐term data remains limited.
- Open Access
- 12 February 2025
- Published by BMJ in BMJ Surgery, Interventions, & Health Technologies
- Vol. 7 (1) , e000193
Capacity assessment for EHR-based medical device post-market surveillance for synthetic mid-urethral slings among women with stress urinary incontinence: a NEST consortium study
Objectives: To evaluate the feasibility for use of electronic health record (EHR) data in conducting adverse event surveillance among women who received mid-urethral slings (MUS) to treat stress urinary incontinence (SUI) in five health systems. Design: Retrospective observational study using EHR data from 2010 through 2021. Women with a history of MUS were identified using common data models; a common analytic code was executed at each site. A manual chart review was conducted in a per-site random patient subset to establish a reference standard. Automated text processing (Text Processed Integrated (TPI)) was developed and evaluated at each site to determine the surgical approach and synthetic mesh implantation. Patients were characterized and surgical outcomes were ascertained over 730 subsequent days. Setting: Five large tertiary care academic medical centers. Participants: Across five health systems, 9,906 eligible patients (mean age 57–60 per site) were identified. Main outcome measures: Determination of surgical approach, synthetic mesh implantation, and assessment of the duration of surveillance for mortality and reoperation rates following MUS implantation. Results: In the TPI cohort analysis, 3,331 patients were identified. Surgical approach per site was retropubic (42% to 77%), transobturator (6% to 44%), single incision (0% to 24%), and adjustable sling (0% to <4%). Concordance rates for TPI using chart review were 71%–90% at each site for the surgical approach and 28%–85% for synthetic mesh implantation. Patient follow-up observation rates for mortality and reoperation ranged from 22% to 36% at 90 days, 15% to 30% at 365 days, and 8% to 19% at 730 days. Conclusion: Using EHR data alone, identification of medical devices and surgical approaches was feasible among women with MUS surgery for SUI, but long-term follow-up ascertainment rates were low. Medical device surveillance using EHR data should be evaluated in the context of the clinical use case, as applicability may vary.
- 12 February 2025
- Published by BMJ in BMJ Surgery, Interventions, & Health Technologies
- Vol. 7 (1) , e000193
Open AccessCapacity assessment for EHR-based medical device post-market surveillance for synthetic mid-urethral slings among women with stress urinary incontinence: a NEST consortium study
Objectives: To evaluate the feasibility for use of electronic health record (EHR) data in conducting adverse event surveillance among women who received mid-urethral slings (MUS) to treat stress urinary incontinence (SUI) in five health systems. Design: Retrospective observational study using EHR data from 2010 through 2021. Women with a history of MUS were identified using common data models; a common analytic code was executed at each site. A manual chart review was conducted in a per-site random patient subset to establish a reference standard. Automated text processing (Text Processed Integrated (TPI)) was developed and evaluated at each site to determine the surgical approach and synthetic mesh implantation. Patients were characterized and surgical outcomes were ascertained over 730 subsequent days. Setting: Five large tertiary care academic medical centers. Participants: Across five health systems, 9,906 eligible patients (mean age 57–60 per site) were identified. Main outcome measures: Determination of surgical approach, synthetic mesh implantation, and assessment of the duration of surveillance for mortality and reoperation rates following MUS implantation. Results: In the TPI cohort analysis, 3,331 patients were identified. Surgical approach per site was retropubic (42% to 77%), transobturator (6% to 44%), single incision (0% to 24%), and adjustable sling (0% to <4%). Concordance rates for TPI using chart review were 71%–90% at each site for the surgical approach and 28%–85% for synthetic mesh implantation. Patient follow-up observation rates for mortality and reoperation ranged from 22% to 36% at 90 days, 15% to 30% at 365 days, and 8% to 19% at 730 days. Conclusion: Using EHR data alone, identification of medical devices and surgical approaches was feasible among women with MUS surgery for SUI, but long-term follow-up ascertainment rates were low. Medical device surveillance using EHR data should be evaluated in the context of the clinical use case, as applicability may vary.
- 24 March 2024
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 231 (2) , 235.e1-235.e16
Defining success after surgical treatment of stress urinary incontinence
- 24 March 2024
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 231 (2) , 235.e1-235.e16
Defining success after surgical treatment of stress urinary incontinence
- 1 February 2023
- Published by SAGE Publications in Journal of Gynecologic Surgery
- Vol. 39 (1) , 2
Pelvic Organ Prolapse
Journal of Gynecologic Surgery
- 1 February 2023
- Published by SAGE Publications in Journal of Gynecologic Surgery
- Vol. 39 (1) , 2
Pelvic Organ Prolapse
Journal of Gynecologic Surgery
- 9 January 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 161 (2) , 655-660
Abdominal and robotic sacrocolpopexy costs following implementation of enhanced recovery after surgery
ObjectiveTo compare perioperative costs and morbidity between open and robotic sacrocolpopexy after implementation of enhanced recovery after surgery (ERAS) pathway. MethodsThe present retrospective cohort study of patients undergoing open or robotic sacrocolpopexy (January 1, 2014, through November 30, 2017) used an ERAS protocol with liposomal bupivacaine infiltration of laparotomy incisions. Primary outcomes were costs associated with index surgery and hospitalization, determined with Medicare cost-to-charge ratios and reimbursement rates and adjusted for variables expected to impact costs. Secondary outcomes included narcotic use, length of stay (LOS), and complications from index hospitalization to postoperative day 30. ResultsFor the total of 231 patients (open cohort, 90; robotic cohort, 141), the adjusted mean cost of robotic surgery was $3239 higher compared with open sacrocolpopexy (95% confidence interval [CI] $1331-$5147; P < 0.001). Rates were not significantly different for intraoperative complications (robotic, 4.3% [6/141]; open, 5.6% [5/90]; P = 0.754), 30-day postoperative complications (robotic, 11.4% [16/141]; open, 16.7% [15/90]; P = 0.322), or readmissions (robotic, 5.7% [8/141]; open, 3.3% [3/90]; P = 0.535). The percentage of patients dismissed on postoperative day 1 was greater in the robotic group (89.4% [126/141] vs. 48.9% [44/90], P < 0.001). ConclusionsDecreased LOS associated with ERAS provided significant cost savings with open sacrocolpopexy versus robotic sacrocolpopexy without adverse impacts on perioperative complications or readmissions.
- 9 January 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 161 (2) , 655-660
Abdominal and robotic sacrocolpopexy costs following implementation of enhanced recovery after surgery
ObjectiveTo compare perioperative costs and morbidity between open and robotic sacrocolpopexy after implementation of enhanced recovery after surgery (ERAS) pathway. MethodsThe present retrospective cohort study of patients undergoing open or robotic sacrocolpopexy (January 1, 2014, through November 30, 2017) used an ERAS protocol with liposomal bupivacaine infiltration of laparotomy incisions. Primary outcomes were costs associated with index surgery and hospitalization, determined with Medicare cost-to-charge ratios and reimbursement rates and adjusted for variables expected to impact costs. Secondary outcomes included narcotic use, length of stay (LOS), and complications from index hospitalization to postoperative day 30. ResultsFor the total of 231 patients (open cohort, 90; robotic cohort, 141), the adjusted mean cost of robotic surgery was $3239 higher compared with open sacrocolpopexy (95% confidence interval [CI] $1331-$5147; P < 0.001). Rates were not significantly different for intraoperative complications (robotic, 4.3% [6/141]; open, 5.6% [5/90]; P = 0.754), 30-day postoperative complications (robotic, 11.4% [16/141]; open, 16.7% [15/90]; P = 0.322), or readmissions (robotic, 5.7% [8/141]; open, 3.3% [3/90]; P = 0.535). The percentage of patients dismissed on postoperative day 1 was greater in the robotic group (89.4% [126/141] vs. 48.9% [44/90], P < 0.001). ConclusionsDecreased LOS associated with ERAS provided significant cost savings with open sacrocolpopexy versus robotic sacrocolpopexy without adverse impacts on perioperative complications or readmissions.
- Open Access
- 31 October 2022
- Published by Springer Nature in npj Regenerative Medicine
- Vol. 7 (1) , 1
Author Correction: Exosome biopotentiated hydrogel restores damaged skeletal muscle in a porcine model of stress urinary incontinence
- 31 October 2022
- Published by Springer Nature in npj Regenerative Medicine
- Vol. 7 (1) , 1
Open AccessAuthor Correction: Exosome biopotentiated hydrogel restores damaged skeletal muscle in a porcine model of stress urinary incontinence
- Open Access
- 29 September 2022
- Published by Springer Nature in npj Regenerative Medicine
- Vol. 7 (1) , 1-17
Exosome biopotentiated hydrogel restores damaged skeletal muscle in a porcine model of stress urinary incontinence
Urinary incontinence afflicts up to 40% of adult women in the United States. Stress urinary incontinence (SUI) accounts for approximately one-third of these cases, precipitating ~200,000 surgical procedures annually. Continence is maintained through the interplay of sub-urethral support and urethral sphincter coaptation, particularly during activities that increase intra-abdominal pressure. Currently, surgical correction of SUI focuses on the re-establishment of sub-urethral support. However, mesh-based repairs are associated with foreign body reactions and poor localized tissue healing, which leads to mesh exposure, prompting the pursuit of technologies that restore external urethral sphincter function and limit surgical risk. The present work utilizes a human platelet-derived CD41a and CD9 expressing extracellular vesicle product (PEP) enriched for NF-κB and PD-L1 and derived to ensure the preservation of lipid bilayer for enhanced stability and compatibility with hydrogel-based sustained delivery approaches. In vitro, the application of PEP to skeletal muscle satellite cells in vitro drove proliferation and differentiation in an NF-κB-dependent fashion, with full inhibition of impact on exposure to resveratrol. PEP biopotentiation of collagen-1 and fibrin glue hydrogel achieved sustained exosome release at 37 °C, creating an ultrastructural “bead on a string” pattern on scanning electron microscopy. Initial testing in a rodent model of latissimus dorsi injury documented activation of skeletal muscle proliferation of healing. In a porcine model of stress urinary incontinence, delivery of PEP-biopotentiated collagen-1 induced functional restoration of the external urethral sphincter. The histological evaluation found that sustained PEP release was associated with new skeletal muscle formation and polarization of local macrophages towards the regenerative M2 phenotype. The results provided herein serve as the first description of PEP-based biopotentiation of hydrogels implemented to restore skeletal muscle function and may serve as a promising approach for the nonsurgical management of SUI.
- 29 September 2022
- Published by Springer Nature in npj Regenerative Medicine
- Vol. 7 (1) , 1-17
Open AccessExosome biopotentiated hydrogel restores damaged skeletal muscle in a porcine model of stress urinary incontinence
Urinary incontinence afflicts up to 40% of adult women in the United States. Stress urinary incontinence (SUI) accounts for approximately one-third of these cases, precipitating ~200,000 surgical procedures annually. Continence is maintained through the interplay of sub-urethral support and urethral sphincter coaptation, particularly during activities that increase intra-abdominal pressure. Currently, surgical correction of SUI focuses on the re-establishment of sub-urethral support. However, mesh-based repairs are associated with foreign body reactions and poor localized tissue healing, which leads to mesh exposure, prompting the pursuit of technologies that restore external urethral sphincter function and limit surgical risk. The present work utilizes a human platelet-derived CD41a and CD9 expressing extracellular vesicle product (PEP) enriched for NF-κB and PD-L1 and derived to ensure the preservation of lipid bilayer for enhanced stability and compatibility with hydrogel-based sustained delivery approaches. In vitro, the application of PEP to skeletal muscle satellite cells in vitro drove proliferation and differentiation in an NF-κB-dependent fashion, with full inhibition of impact on exposure to resveratrol. PEP biopotentiation of collagen-1 and fibrin glue hydrogel achieved sustained exosome release at 37 °C, creating an ultrastructural “bead on a string” pattern on scanning electron microscopy. Initial testing in a rodent model of latissimus dorsi injury documented activation of skeletal muscle proliferation of healing. In a porcine model of stress urinary incontinence, delivery of PEP-biopotentiated collagen-1 induced functional restoration of the external urethral sphincter. The histological evaluation found that sustained PEP release was associated with new skeletal muscle formation and polarization of local macrophages towards the regenerative M2 phenotype. The results provided herein serve as the first description of PEP-based biopotentiation of hydrogels implemented to restore skeletal muscle function and may serve as a promising approach for the nonsurgical management of SUI.
- 15 June 2022
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 159 (3) , 727-734
Impact of enhanced recovery implementation in women undergoing abdominal sacrocolpopexy
Objective: To assess the effect of Enhanced Recovery After Surgery (ERAS) with and without liposomal bupivacaine (LB) on opioid use, hospital length of stay (LOS), costs, and morbidity of women undergoing sacrocolpopexy. Methods: Retrospective cohort of women who underwent abdominal sacrocolpopexy between April 1, 2009 and November 30, 2017. Costs for relevant healthcare services were determined by assigning 2017 charges multiplied by 2017 Medicare Cost Report's cost to charge ratios. Outcomes were compared among periods with multivariable regression models adjusted for age, American Society of Anesthesiologists score, and concurrent hysterectomy and posterior repair. Results: Patients were subdivided into pre‐ERAS (G1, n = 128), post‐ERAS (G2, n = 83), and post‐ERAS plus LB (G3, n = 91). The proportion of patients needing opioids during postoperative days 0–2 was significantly less for G3 (75.8%) compared with G1 (97.7%) and G2 (92.8%); P < 0.001). The median morphine equivalent units (MEU) with interquartile ranges, mean LOS, and adjusted mean standardized costs were significantly lower in G3 compared with the other two groups (35 [20–75] vs. 67 [31–109], and 60 [30–122] MEUs; 1.8 vs. 2.3 vs. 2.9 days; and $2391, $2975, and $3844, for G3, G2, and G1, respectively; P < 0.001). Conclusion: Implementation of an ERAS pathway led to significant decreases in opioid use, LOS, and costs. Supplementation with LB further improved these measures.
- 15 June 2022
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 159 (3) , 727-734
Impact of enhanced recovery implementation in women undergoing abdominal sacrocolpopexy
Objective: To assess the effect of Enhanced Recovery After Surgery (ERAS) with and without liposomal bupivacaine (LB) on opioid use, hospital length of stay (LOS), costs, and morbidity of women undergoing sacrocolpopexy. Methods: Retrospective cohort of women who underwent abdominal sacrocolpopexy between April 1, 2009 and November 30, 2017. Costs for relevant healthcare services were determined by assigning 2017 charges multiplied by 2017 Medicare Cost Report's cost to charge ratios. Outcomes were compared among periods with multivariable regression models adjusted for age, American Society of Anesthesiologists score, and concurrent hysterectomy and posterior repair. Results: Patients were subdivided into pre‐ERAS (G1, n = 128), post‐ERAS (G2, n = 83), and post‐ERAS plus LB (G3, n = 91). The proportion of patients needing opioids during postoperative days 0–2 was significantly less for G3 (75.8%) compared with G1 (97.7%) and G2 (92.8%); P < 0.001). The median morphine equivalent units (MEU) with interquartile ranges, mean LOS, and adjusted mean standardized costs were significantly lower in G3 compared with the other two groups (35 [20–75] vs. 67 [31–109], and 60 [30–122] MEUs; 1.8 vs. 2.3 vs. 2.9 days; and $2391, $2975, and $3844, for G3, G2, and G1, respectively; P < 0.001). Conclusion: Implementation of an ERAS pathway led to significant decreases in opioid use, LOS, and costs. Supplementation with LB further improved these measures.
- 1 April 2021
- Published by SAGE Publications in Journal of Gynecologic Surgery
- Vol. 37 (2) , 101-106
Route of Hysterectomy: Vaginal
Vaginal hysterectomy is considered the preferred approach for benign hysterectomy due to its cost-effectiveness, safety, and low morbidity. Efforts to increase vaginal hysterectomy utilization, including endorsement by the American College of Obstetricians and Gynecologists and the American Association of Gynecologic Laparoscopists, has had limited impact on national trends. Marketing from companies and shifts in practice patterns along with lack of resident education have exacerbated the problem. Deeply engrained, though unfounded, perceived contraindications to a vaginal approach (e.g., prior surgery, nulliparity, uterine size, and risk factors for extrauterine disease) limits consideration of this approach further. This review presents evidence against these commonly perceived contraindications and provides a peer-reviewed algorithm that can be implemented to increase vaginal hysterectomy utilization safely. As minimally invasive technologies continue to evolve, surgeons have the responsibility to seek candidates that would benefit from the original—and most minimally invasive—approach to benign hysterectomy. (J GYNECOL SURG 20XX:000)
- 1 April 2021
- Published by SAGE Publications in Journal of Gynecologic Surgery
- Vol. 37 (2) , 101-106
Route of Hysterectomy: Vaginal
Vaginal hysterectomy is considered the preferred approach for benign hysterectomy due to its cost-effectiveness, safety, and low morbidity. Efforts to increase vaginal hysterectomy utilization, including endorsement by the American College of Obstetricians and Gynecologists and the American Association of Gynecologic Laparoscopists, has had limited impact on national trends. Marketing from companies and shifts in practice patterns along with lack of resident education have exacerbated the problem. Deeply engrained, though unfounded, perceived contraindications to a vaginal approach (e.g., prior surgery, nulliparity, uterine size, and risk factors for extrauterine disease) limits consideration of this approach further. This review presents evidence against these commonly perceived contraindications and provides a peer-reviewed algorithm that can be implemented to increase vaginal hysterectomy utilization safely. As minimally invasive technologies continue to evolve, surgeons have the responsibility to seek candidates that would benefit from the original—and most minimally invasive—approach to benign hysterectomy. (J GYNECOL SURG 20XX:000)
- 1 September 2018
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 132 (3) , 736-740
The Rise and Fall of Mesh in Pelvic Surgery and the Shortcomings of Medical Device Regulation
Two U.S. Food and Drug Administration public health warnings regarding the use of mesh in stress incontinence and prolapse repairs have had far-reaching clinical and legal consequences. In this commentary, we explore the drastically distinct results from these mesh-based procedures, which revealed systemic flaws with the medical device approval process across specialties and affected thousands of patients.
- 1 September 2018
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 132 (3) , 736-740
The Rise and Fall of Mesh in Pelvic Surgery and the Shortcomings of Medical Device Regulation
Two U.S. Food and Drug Administration public health warnings regarding the use of mesh in stress incontinence and prolapse repairs have had far-reaching clinical and legal consequences. In this commentary, we explore the drastically distinct results from these mesh-based procedures, which revealed systemic flaws with the medical device approval process across specialties and affected thousands of patients.